Head to Head Review: Landstar (OTCMKTS:LDSR) & Cyclo Therapeutics (NASDAQ:CYTH)


Share on StockTwits

Cyclo Therapeutics (NASDAQ:CYTH) and Landstar (OTCMKTS:LDSR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings and risk.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Cyclo Therapeutics and Landstar, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclo Therapeutics 0 0 1 0 3.00
Landstar 0 0 0 0 N/A

Cyclo Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 130.77%. Given Cyclo Therapeutics’ higher probable upside, research analysts plainly believe Cyclo Therapeutics is more favorable than Landstar.

Valuation and Earnings

This table compares Cyclo Therapeutics and Landstar’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cyclo Therapeutics $1.01 million 8.75 -$7.53 million N/A N/A
Landstar $30,000.00 2,087.39 -$15.09 million N/A N/A

Cyclo Therapeutics has higher revenue and earnings than Landstar.

Volatility and Risk

Cyclo Therapeutics has a beta of -1, suggesting that its share price is 200% less volatile than the S&P 500. Comparatively, Landstar has a beta of -10.88, suggesting that its share price is 1,188% less volatile than the S&P 500.

Profitability

This table compares Cyclo Therapeutics and Landstar’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cyclo Therapeutics -903.35% -4,537.83% -278.21%
Landstar N/A N/A N/A

Summary

Cyclo Therapeutics beats Landstar on 5 of the 9 factors compared between the two stocks.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc., a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. It has a collaboration with the Chattanooga Center for Neurologic Research. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in October 2019. Cyclo Therapeutics, Inc. was founded in 1990 and is based in Gainesville, Florida.

Landstar Company Profile

LandStar, Inc. a technology company, develops and acquires various cyber-security products and services. Its products and services are central to cyber data security, GDPR, compliance, and governance capabilities. LandStar, Inc. was founded in 1990 and is based in Raleigh, North Carolina.

Receive News & Ratings for Cyclo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.